Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells

Raviraja N. Seetharam, Arjun Sood, Atrayee Basu-Mallick, Leonard H. Augenlicht, John M. Mariadason, Sanjay Goel

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Oxaliplatin is used to treat patients with colorectal cancer (CRC); however, half the patients fail to benefit. The excision repair cross-complementing group-1 (ERCC1) gene was studied and it was hypothesized that its inducible expression contributes to cellular resistance. Materials and Methods: Thirty CRC cell lines were treated with oxaliplatin and sensitivity was determined by apoptosis. Four sensitive and resistant cell lines were analyzed for oxaliplatin effect on ERCC1 expression and two resistant cell lines were subjected to siRNA-mediated gene silencing. Results: There was no correlation of basal ERCC1 mRNA expression with response to oxaliplatin. ERCC1 mRNA was induced at 24, 48, and 72 hours (71-264%, p<0.05) and ERCC1 protein at 48 hours (123-521%, p<0.05) post-oxaliplatin treatment in resistant cells only. siRNA-mediated silencing of ERCC1 sensitized the CRC cells to oxaliplatin-induced apoptosis, and increased cleaved PARP. Conclusion: ERCC1 gene expression is inducible, contributes to oxaliplatin resistance, and is reversible by targeted suppression of ERCC1, identifying ERCC1 as a potential target for drug development.

Original languageEnglish (US)
Pages (from-to)2531-2538
Number of pages8
JournalAnticancer Research
Volume30
Issue number7
StatePublished - Jul 2010

Fingerprint

oxaliplatin
Gene Silencing
DNA Repair
Small Interfering RNA
Colorectal Neoplasms
Up-Regulation
Cell Line
Apoptosis
Messenger RNA

Keywords

  • Colorectal cancer
  • ERCC1
  • Gene silencing
  • Oxaliplatin
  • Resistance
  • siRNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells. / Seetharam, Raviraja N.; Sood, Arjun; Basu-Mallick, Atrayee; Augenlicht, Leonard H.; Mariadason, John M.; Goel, Sanjay.

In: Anticancer Research, Vol. 30, No. 7, 07.2010, p. 2531-2538.

Research output: Contribution to journalArticle

Seetharam, Raviraja N. ; Sood, Arjun ; Basu-Mallick, Atrayee ; Augenlicht, Leonard H. ; Mariadason, John M. ; Goel, Sanjay. / Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells. In: Anticancer Research. 2010 ; Vol. 30, No. 7. pp. 2531-2538.
@article{1e46afbea2c34946b89bbc91eb348fa5,
title = "Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells",
abstract = "Background: Oxaliplatin is used to treat patients with colorectal cancer (CRC); however, half the patients fail to benefit. The excision repair cross-complementing group-1 (ERCC1) gene was studied and it was hypothesized that its inducible expression contributes to cellular resistance. Materials and Methods: Thirty CRC cell lines were treated with oxaliplatin and sensitivity was determined by apoptosis. Four sensitive and resistant cell lines were analyzed for oxaliplatin effect on ERCC1 expression and two resistant cell lines were subjected to siRNA-mediated gene silencing. Results: There was no correlation of basal ERCC1 mRNA expression with response to oxaliplatin. ERCC1 mRNA was induced at 24, 48, and 72 hours (71-264{\%}, p<0.05) and ERCC1 protein at 48 hours (123-521{\%}, p<0.05) post-oxaliplatin treatment in resistant cells only. siRNA-mediated silencing of ERCC1 sensitized the CRC cells to oxaliplatin-induced apoptosis, and increased cleaved PARP. Conclusion: ERCC1 gene expression is inducible, contributes to oxaliplatin resistance, and is reversible by targeted suppression of ERCC1, identifying ERCC1 as a potential target for drug development.",
keywords = "Colorectal cancer, ERCC1, Gene silencing, Oxaliplatin, Resistance, siRNA",
author = "Seetharam, {Raviraja N.} and Arjun Sood and Atrayee Basu-Mallick and Augenlicht, {Leonard H.} and Mariadason, {John M.} and Sanjay Goel",
year = "2010",
month = "7",
language = "English (US)",
volume = "30",
pages = "2531--2538",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "7",

}

TY - JOUR

T1 - Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells

AU - Seetharam, Raviraja N.

AU - Sood, Arjun

AU - Basu-Mallick, Atrayee

AU - Augenlicht, Leonard H.

AU - Mariadason, John M.

AU - Goel, Sanjay

PY - 2010/7

Y1 - 2010/7

N2 - Background: Oxaliplatin is used to treat patients with colorectal cancer (CRC); however, half the patients fail to benefit. The excision repair cross-complementing group-1 (ERCC1) gene was studied and it was hypothesized that its inducible expression contributes to cellular resistance. Materials and Methods: Thirty CRC cell lines were treated with oxaliplatin and sensitivity was determined by apoptosis. Four sensitive and resistant cell lines were analyzed for oxaliplatin effect on ERCC1 expression and two resistant cell lines were subjected to siRNA-mediated gene silencing. Results: There was no correlation of basal ERCC1 mRNA expression with response to oxaliplatin. ERCC1 mRNA was induced at 24, 48, and 72 hours (71-264%, p<0.05) and ERCC1 protein at 48 hours (123-521%, p<0.05) post-oxaliplatin treatment in resistant cells only. siRNA-mediated silencing of ERCC1 sensitized the CRC cells to oxaliplatin-induced apoptosis, and increased cleaved PARP. Conclusion: ERCC1 gene expression is inducible, contributes to oxaliplatin resistance, and is reversible by targeted suppression of ERCC1, identifying ERCC1 as a potential target for drug development.

AB - Background: Oxaliplatin is used to treat patients with colorectal cancer (CRC); however, half the patients fail to benefit. The excision repair cross-complementing group-1 (ERCC1) gene was studied and it was hypothesized that its inducible expression contributes to cellular resistance. Materials and Methods: Thirty CRC cell lines were treated with oxaliplatin and sensitivity was determined by apoptosis. Four sensitive and resistant cell lines were analyzed for oxaliplatin effect on ERCC1 expression and two resistant cell lines were subjected to siRNA-mediated gene silencing. Results: There was no correlation of basal ERCC1 mRNA expression with response to oxaliplatin. ERCC1 mRNA was induced at 24, 48, and 72 hours (71-264%, p<0.05) and ERCC1 protein at 48 hours (123-521%, p<0.05) post-oxaliplatin treatment in resistant cells only. siRNA-mediated silencing of ERCC1 sensitized the CRC cells to oxaliplatin-induced apoptosis, and increased cleaved PARP. Conclusion: ERCC1 gene expression is inducible, contributes to oxaliplatin resistance, and is reversible by targeted suppression of ERCC1, identifying ERCC1 as a potential target for drug development.

KW - Colorectal cancer

KW - ERCC1

KW - Gene silencing

KW - Oxaliplatin

KW - Resistance

KW - siRNA

UR - http://www.scopus.com/inward/record.url?scp=77955792964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955792964&partnerID=8YFLogxK

M3 - Article

C2 - 20682979

AN - SCOPUS:77955792964

VL - 30

SP - 2531

EP - 2538

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 7

ER -